Using SCC Antigen and CRP Levels as Prognostic Biomarkers in Recurrent Oral Cavity Squamous Cell Carcinoma

Squamous cell carcinoma antigen (SCC-Ag) and C-reactive protein (CRP) levels have been successfully used to stratify risk groups in primary oral squamous cell carcinoma (OSCC) patients; however, related biomarkers have rarely been investigated in recurrent OSCC. The purpose of the present study was...

Full description

Saved in:
Bibliographic Details
Published in:PloS one Vol. 9; no. 7; p. e103265
Main Authors: Chen, I-How, Liao, Chun-Ta, Wang, Hung-Ming, Huang, Jung-Ju, Kang, Chung-Jan, Huang, Shiang-Fu
Format: Journal Article
Language:English
Published: United States Public Library of Science 25.07.2014
Public Library of Science (PLoS)
Subjects:
Adult
Aged
Aged, 80 and over
Antigens
Antigens, Neoplasm - blood
Bioindicators
Biological markers
Biology and Life Sciences
Biomarkers
Biomarkers, Tumor - blood
C-reactive protein
C-Reactive Protein - metabolism
Cancer therapies
Carcinoma, Squamous Cell - blood
Colorectal cancer
Diagnosis
Dissection
Female
Hospitals
Humans
Inflammation
Male
Medical diagnosis
Medical prognosis
Medical treatment
Medicine and Health Sciences
Metastases
Middle Aged
Mouth Neoplasms - blood
Neck
NMR
Nuclear magnetic resonance
Oral cavity
Oral squamous cell carcinoma
Otolaryngology
Patients
Prognosis
Proteins
Radiation therapy
Risk groups
Serpins - blood
Squamous cell carcinoma
Survival
Tomography
Tumors
Ultrasonic imaging
Taiwan
ISSN:1932-6203, 1932-6203
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Squamous cell carcinoma antigen (SCC-Ag) and C-reactive protein (CRP) levels have been successfully used to stratify risk groups in primary oral squamous cell carcinoma (OSCC) patients; however, related biomarkers have rarely been investigated in recurrent OSCC. The purpose of the present study was to analyze the relationships of SCC-Ag and CRP levels at the time of recurrence with clinical factors and prognosis. We retrospectively recruited patients with recurrence in a cohort of 534 OSCC patients between March 2001 and July 2013. One hundred patients had recurrence. The serum SCC-Ag and CRP levels were measured at the time of cancer diagnosis, 3 to 6 months after treatment with clinical disease-free, and at the time of recurrence. The SCC-Ag levels were significantly lowered after treatment (paired t-test: p = 0.001) and re-elevated at the time of recurrence (paired t-test: p = 0.027). An SCC-Ag level ≥2.0 ng/ml and a CRP level ≥5.0 mg/L at the time of recurrence were significantly associated with recurrent tumor status (P<0.001), recurrent nodal metastasis (χ2 trend test: P = 0.020), distant metastasis (P<0.001), and overall survival (P<0.001). Moreover, the influence of both elevated SCC-Ag and CRP levels on overall survival (P<0.001, H.R. [95% CI]: 5.406 [2.210-13.222]) still existed after adjusting for the recurrent tumor stage and patient age. The present study demonstrates that concurrent high levels of both SCC-Ag and CRP at the diagnosis of recurrence acts as a predictor of recurrent tumor status, recurrent advanced tumor stage, distant metastasis, and survival after the diagnosis of recurrence. This study expands the applicability of these two markers in the risk stratification in recurrent OSCC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Conceived and designed the experiments: IHC SFH. Performed the experiments: IHC SFH. Analyzed the data: SFH. Contributed reagents/materials/analysis tools: IHC CTL CJK SFH. Wrote the paper: IHC SFH. Data acquisition: CTL HMW JJH CJK.
Competing Interests: The authors have declared that no competing interests exist.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0103265